UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2024
Commission File Number: 001-38455
MorphoSys AG
(Exact name of registrant as specified in its charter)
Semmelweisstrasse 7
82152 Planegg
Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
☒ Form 20-F ☐ Form 40-F
On June 20, 2024, MorphoSys AG (the “Company”) published an ad hoc announcing Novartis BidCo Germany has informed the Company’s Management Board of its intention to implement a merger squeeze-out of the Company’s minority shareholders.
Exhibits
99.1 | Ad Hoc Announcement, dated June 20, 2024 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MorphoSys AG | ||||||||
Date: June 20, 2024 | By: | /s/ i.V. Julia Neugebauer | ||||||
Name: Dr. Julia Neugebauer | ||||||||
Title: Global Head of IR | ||||||||
Date: June 20, 2024 | By: | /s/ i.A. Isabelle Degbegni | ||||||
Name: Isabelle Degbegni | ||||||||
Title: Director Investor Relations |